Articles – Genomic Testing Cooperative

Peripheral Blood Tumor Associated Cell-Free DNA Testing as a Predictor for Relapse Postallogeneic Stem Cell Transplant for Acute Myelogenous Leukemia

October 9, 2025

Authors: Vanisha Patel1,*, Maciej Kabat1, Andrew Ip2, Sukhdeep Kaur2, Hyung Chan Suh2, Christina Cho2, David Vesole2, Michele Donato2, Maher Albitar2, Scott D. Rowley2 Affiliations:1Hackensack University Medical Center, Hackensack, New Jersey2John Theurer Cancer Center, Hackensack, New Jersey Article history: Received 9 May 2025 | Accepted 11 August 2025 Abstract Allogeneic stem

GTC featured in OC Business Journal

April 16, 2025

GTC Expands Cancer Tests to Europe via Partnership By Yuika Yoshida April 7, 2025 Genomic Testing Cooperative (GTC) is expanding into the European market by partnering with German laboratory Labor Dr. Wisplinghoff. “Our diagnostics tests going out of the U.S. to Europe is democratizing science,” Chief Executive Dr. Maher Albitar told the

BioAI and Genomic Testing Cooperative Announce Strategic Collaboration to Provide AI-Powered Digital Pathology Solutions for Clinical Research and Diagnostic Applications

June 25, 2024

Manchester, NH – June 25, 2024 – BioAI, an emerging biotech company applying multimodal artificial intelligence (AI) to novel biomarker discovery, development, and diagnostics, announced a strategic collaboration with Genomic Testing Cooperative (GTC), a leading provider of molecular diagnostics for solid tumors and hematologic malignancies. This collaboration leverages the

New publication on how cfRNA and AI are advancing LBx

May 23, 2023

GTC has a new publication in Heliyon titled “The Potential of Cell-Free RNA in Liquid Biopsy: Comprehensive Analysis of Mutation Profile, Chromosomal Abnormalities, and Immune Biomarkers”. This study explores the potential of cell-free RNA (cfRNA) and AI as valuable components of liquid biopsy for evaluating the host immune system and

Case Study: VEXAS Syndrome

June 8, 2022

Background VEXAS syndrome is a disease with inflammatory and hematologic (blood) manifestations. The syndrome is caused by mutations in the UBA1 gene affecting the Met41 residue of the protein and resulting in decreased cellular ubiquitylation activity and hyperinflammation. This is an adults-onset fatal disease that may present as myelodysplastic syndrome, aplastic anemia

What are some of the hematologic manifestations of VEXAS syndrome?

March 16, 2022

A Man with a Recurrent Left Pleural Effusion In late 2020, a new disease entity that was referred to as VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome was reported. Q: What is the cause of VEXAS syndrome?A: VEXAS syndrome is caused by somatic mutations in UBA1 (the gene that encodes ubiquitin-like modifier activating enzyme 1),

GTC scientists contribute to major study published in Journal of Clinical Oncology: Prediction of outcome in CLL patients

October 8, 2020

GTC scientists collaborate with the NIH on a study just published in the Journal of Clinical Oncology. The publication is titled: Prediction of outcome in CLL patients treated with ibrutinib: development and validation of a four-factor prognostic model. You can read the article here (subscription required). Abstract: PURPOSE Randomized trials established the

Genomic Testing Cooperative Aims to Expand Clinical, Commercial NGS Access With Co-Op Model

August 26, 2020

Jul 23, 2020 | John Gilmore NEW YORK – As part of plans to establish a country-wide network of labs for minimizing the cost of sequencing, Genomic Testing Cooperative (GTC) has launched a joint venture with Hackensack Meridian Health (HMH) that will analyze clinical samples from patients with a variety

Utilize the first AI software for diagnosing DLBCL

August 5, 2020

Do not accept partial results, send your lymphoma to GTC for comprehensive classification using RNA/DNA and artificial intelligence. Get results in 7 days for DNA and 10 days for RNA GTC was recently published in Blood Advances with an article titled (click URL below to read it):A refined cell-of-origin classifier

Hackensack Meridian Health Partners with GTC to Establish a Reference Laboratory Offering State-of-the-Art Genomic Precision Testing

July 22, 2020

IRVINE, Calif. and EDISON, N.J., July 22, 2020 /PRNewswire/ — Hackensack Meridian Health (HMH) in Edison, New Jersey, and Genomic Testing Cooperative (GTC), Irvine, California, announced today an agreement to establish a next generation sequencing reference laboratory for molecular profiling. The state-of-the-art laboratory, located at JFK Medical Center in Edison, New Jersey, will

Category: Articles